Thinnayam Naganathan Krishnamurthy

This inventor holds 18 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Euro-Celtique S.a., Rhodes Pharmaceuticals L.p., Purdue Pharma L.p.. Active years: 1993-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thinnayam Naganathan Krishnamurthy. Retrieved from https://idiyas.com/inventor/thinnayam-naganathan-krishnamurthy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 2)

% Patents Active = 50.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.0

ph-index = 11

Forward Citations = 879(Granted Patents)

Location History:

Ontario, CA (1993 - 2007)
Scarborough, CA (2002 - 2019)

Company Filing History:

Rhodes Pharmaceuticals L.p.

Years Active: 1993-2019

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10463624 - Controlled release formulations (2019-11-05),

2. 10258616 - Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome (2019-04-16),

3. 10039719 - Methods of treating attention deficit hyperactivity disorder (2018-08-07),

4. 10022330 - Methods of preparing oral controlled release formulations (2018-07-17),

5. 9949931 - Methods of treating attention deficit hyperactivity disorder (2018-04-24),

6. 9814710 - Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome (2017-11-14),

7. 9801823 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2017-10-31),

8. 9700508 - Pharmaceutical compositions comprising hydromorphone and naloxone (2017-07-11),

9. 9066869 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2015-06-30),

10. 8580310 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2013-11-12),

11. 7438930 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2008-10-21),

12. 7247318 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2007-07-24),

13. 7083808 - Controlled/modified release oral methylphenidate formulations (2006-08-01),

14. 6673367 - Controlled/modified release oral methylphenidate formulations (2004-01-06),

15. 6419960 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations (2002-07-16),

Title: Thinnayam Naganathan Krishnamurthy: Innovator in Controlled Release Formulations

Introduction

Thinnayam Naganathan Krishnamurthy is a notable inventor based in Scarborough, Canada. He holds an impressive portfolio of 18 patents, showcasing his contributions to the field of pharmaceutical formulations. His work primarily focuses on developing innovative drug delivery systems that enhance therapeutic efficacy.

Latest Patents

Among his latest patents, one significant invention is related to controlled release formulations. This invention is directed to oral modified/controlled release drug formulations that provide a rapid initial onset of effect and a prolonged duration of effect. The design ensures that the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, with a rapid decline in effect at the end of the dosing interval. Another notable patent involves hydromorphone and naloxone for the treatment of pain and opioid bowel dysfunction syndrome. This invention pertains to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for effective pain management.

Career Highlights

Throughout his career, Thinnayam has worked with reputable companies such as Euro-Celtique S.A. and Rhodes Pharmaceuticals L.P. His experience in these organizations has significantly contributed to his expertise in pharmaceutical innovations.

Collaborations

Thinnayam has collaborated with several professionals in the field, including Andrew Darke and Helen Kathleen Danagher, who have played a role in his research and development efforts.

Conclusion

Thinnayam Naganathan Krishnamurthy's contributions to controlled release formulations and pain management highlight his innovative spirit and dedication to improving pharmaceutical therapies. His work continues to influence the industry and pave the way for future advancements.

Profile summary based on public USPTO records.